Dispensed: CVS Health’s plan to become a go-to spot for healthcare, uBiome’s 75-person advisory boards, and an inside look at a massive generic drug lawsuit
Hope everyone is recovered from the long week of conferences!
I wanted to start this week’s newsletter with a BIG welcome to Clarrie Feinstein, who joins the BI healthcare team as a fellow. Be sure to follow her on Twitter, and in the coming weeks I’ll be highlighting the work she’ll be doing.
She’ll be a big help as we pull together the under 40 in healthcare list I mentioned last week.
Here’s the form for nominations. The deadline for submissions is June 19, but be sure to get them in as soon as possible! We’re looking for rising stars within the healthcare industry bringing interesting ideas to their roles — regardless of whether it’s in the C-Suite or earlier in their careers.
This week was filled with big updates on CVS Health’s strategy, walk-in clinic scoops, details on uBiome’s scientific advisers, and more.
A lot of people in the industry announced new roles this week. Merck’s Adam Schechter is slated to be the next LabCorp CEO, while former Juno Therapeutics CEO Hans Bishop is stepping in as CEO of preventive cancer diagnostic company Grail. Today, Sanofi announced that Novartis Pharmaceuticals’ unit CEO Paul Hudson will be its next CEO, replacing Olivier Brandicourt. (Funny enough, I chatted with both Sanofi and Hudson earlier this year about the potential of digital therapeutics!)
Are you new to our newsletter? You can sign up for Dispensed here.
To start, thought, a quick final word on how health insurers fared in Q1: Bright Health at the end of May posted a final filing, showing that theMinnesota-based venture-backed insurer made a profit of $15.3 million over the period.
You can read about Bright Health’s plans for expansion in the coming years — as well as Oscar’s and …read more
Source:: Business Insider